Antivirals for 2010/11 flu season

Recommendations issued by NICE for antiviral use during the 2009/10 influenza pandemic have come into force again.

Tamiflu (oseltamivir) is taken orally as capsules or liquid; Relenza (zanamivir) comes as powder for inhalation.
Tamiflu (oseltamivir) is taken orally as capsules or liquid; Relenza (zanamivir) comes as powder for inhalation.

The guidance has been readopted for the current flu season in line with national surveillance data indicating that the H1N1 (2009) virus is now in general circulation. Oseltamivir continues to be recommended, along with zanamivir, for the prophylaxis and treatment of influenza.

The two antivirals can be used when:

  • A person with a flu-like illness is in an ‘at-risk’ group and they can start treatment within 48 hours (or within 36 hours for zanamivir treatment in children) of symptom onset
  • A person with a flu-like illness who has not received the flu vaccine is in an ‘at-risk’ group and they can start treatment within 48 hours (or within 36 hours for zanamivir treatment) of exposure to a person in the same household with flu-like symptoms

Pregnant women have been added to the list of ‘at risk’ individuals.

Letter from the Director of Immunisation

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

NICE recommends new triple therapy option for diabetes

NICE recommends new triple therapy option for diabetes

Ertugliflozin (Steglatro) can now be prescribed routinely...